详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients

144| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究负责人：

研究单位： [1]Peking University First Hospital [2]Peking University First Hospital,Beijing,Beijing,China,100034 [3]Beijing Hospital of the Ministry of Health,Beijing,Beijing,China [4]Beijing YouAn Hospital, Capital Medical University,Beijing,Beijing,China [5]Fuwai Hospital Chinese Academy of Medical Sciences,Beijing,Beijing,China [6]Tongji Hospital, Tongji Medical College of HUST,Wuhan,Hubei,China [7]Wuhan Puai Hospital,Wuhan,Hubei,China [8]Suzhou Municipal Hospital,Suzhou,Jiangsu,China [9]Tianjin Medical University Cancer Institute & Hospital,Tianjin,Tianjin,China [10]Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),Hangzhou,Zhejiang,China [11]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,Zhejiang,China

关键词： Postoperative nausea and vomiting Benzodiazepines High-risk patients

研究目的：

This trial aims to explore whether the intraoperative use of remimazolam can reduce the incidence of postoperative nausea and vomiting (PONV) in high-risk patients. According to the Apfel's simplified score, patients with 3 or more of the following factors are at high risk of postoperative nausea and vomiting (PONV), i.e., women, non-smokers, history of PONV, and postoperative use of opioids.